INTRODUCTION
The most drug-resistant form of tuberculosis (TB), extensively drug-resistant tuberculosis (XDR-TB), is defined as resistance to isoniazid and rifampicin, any fluoroquinolone, and any second-line injectable antimycobacterial agent. 1 XDR-TB/HIV coinfection was first described in an explosive outbreak in rural KwaZulu-Natal, South Africa, in 2006. 2, 3 The initial outbreak was associated with high mortality in the absence of effective treatment and was initially believed to have occurred through primary nosocomial transmission. 2, 3 Epidemiologic and microbiologic studies have identified F15/ LAM4/KZN as the predominant Mycobacterium tuberculosis (MTB) strain in patients with XDR-TB in KwaZulu-Natal. Distinct from other regions of high XDR-TB prevalence, next generation sequencing has shown surprisingly few single nucleotide polymorphism (SNP) differences between geographically dispersed MTB isolates with the inference that ongoing transmission is responsible for a large proportion of XDR-TB cases in this HIV high-burden population. 2, [4] [5] [6] [7] [8] Previous retrospective studies have shown high mortality and very low rates of cure in the treatment of XDR-TB/ HIV. [9] [10] [11] [12] [13] Factors associated with favorable XDR-TB treatment outcomes include treatment with regimens to which the MTB strain is susceptible, access to novel and repurposed agents (including bedaquiline, delamanid, and linezolid), and in patients with HIV coinfection treatment with antiretroviral therapy (ART). 14 ART has been shown to improve mortality in TB/HIV when given early in the TB treatment course, particularly in patients with low CD4 T-cell count. 15, 16 ART is also associated with decreased rates of reactivation in patients with latent TB infection. However, in XDR-TB/HIV, while ART is clearly associated with improved mortality, it is less clear that ART improves MTB culture conversion or other TB-specific outcomes. 17 To comprehensively characterize a cohort of XDR-TB patients living both with and without HIV, to avoid bias introduced by retrospective design, and to capture greater detail about treatment regimens, we analyzed data from a prospectively followed cohort of patients with XDR-TB in KwaZulu-Natal Province, South Africa. We performed this study to characterize treatment outcomes and the effects of ART on TB treatment response and to describe the results of whole genome sequencing (WGS).
METHODS

Study Design
A cohort of consecutive XDR-TB patients was enrolled at a TB referral hospital in KwaZulu-Natal, South Africa, from August 2009 to July 2011 and prospectively followed for greater than 24 months unless death or patient default occurred. Since 2008, KwaZulu-Natal has decentralized the care for drug-resistant TB by initially opening 4 decentralized sites throughout the province, and more recently, 9 decentralized sites for the treatment of drug-resistant TB. Eligible patients were aged 18 years and older, had not been previously treated for XDR-TB and/or molecular evidence, were diagnosed with active TB disease according to South African/WHO guidelines, had culture-proven XDR-TB, agreed to start treatment for XDR-TB, and had capacity to give informed consent. Written consent was obtained by the study. Clinical data, questionnaires, and sputum were collected monthly, and treatment outcomes were assigned according to standard definitions at 24 months after treatment initiation. 18 Culture conversion was defined as 2 consecutive monthly TB cultures without growth of MTB. Net culture conversion was defined as culture conversion without subsequent reversion to MTB culture positivity. Treatment outcomes included cure, treatment completion, lost to follow-up, death, and failure and were defined at 24 months after XDR-TB treatment initiation. Cure was defined as a patient who completed 24 months of treatment with 3 or more consecutive negative MTB cultures taken at least 30 days apart in the last 12 months of treatment. 19 Treatment completion was defined as a patient who completed 24 months of treatment with clinical improvement, but without sufficient negative MTB cultures to qualify for cure. Lost to follow-up (formerly "default") was defined as any patient with XDR-TB whose XDR-TB treatment was interrupted for 2 or more consecutive months. Treatment failure was defined as 2 or more of 5 cultures recorded as positive in the final 12 months of treatment, or if any of the final 3 cultures were positive. We further used a set of modified multidrug-resistant TB (MDR-TB) treatment outcome criteria suggested by Lange et al to define treatment outcomes at 36 months. 20 Under the modified criteria, cure is defined as a negative culture status at 6 months, with no subsequent positive culture or replaces within a year, and failure is defined as a positive culture status at 6 months or relapse after 1 year of treatment. Death was defined as a death during the period of observation, and loss to follow-up was defined as not being in care at 6 months. A status of undeclared was defined as an outcome that was not assessed. This study protocol was approved through the Columbia University Review Board and the Biomedical Research Ethics Council of the University of KwaZulu-Natal.
Laboratory Methods and Whole Genome Sequencing
Sputum for microscopy and MTB culture was obtained monthly as is routine clinical practice. MTB culture positivity was determined using the BACTEC MGIT 960 fluorometric system (Becton Dickinson Diagnostics, Sparks, MD). Drug susceptibility testing for first-line and second-line drugs was performed at a regional TB reference laboratory in Durban, South Africa. Drug susceptibility testing for isoniazid, rifampin, ethambutol, streptomycin, ethionamide, ofloxacin, and kanamycin was by the modified proportional growth method using standard techniques. Molecular susceptibility testing was not routinely performed during the study period.
Mycobacteria were extracted from solid media agar growth media, and genomic MTB DNA was isolated using standard protocols. 21 Library preparation and WGS were performed as previously described using the Illumina HiSeq platform. 22 Raw sequencing reads were trimmed for lowquality bases and aligned to the H37Rv MTB reference genome using the Burrows-Wheeler Aligner. Variants calls were obtained using samtools. Variants in the highly variable PE/PPE gene family, variants in repeat regions or mobile elements, and variants within 15 base pairs of an insertion or deletion were excluded from analysis. High-quality SNPs were defined as those with PHRED-scaled quality scores .100 and .75% of reads supporting the alternate allele. All data were submitted to the NCBI Sequence Read Archive. To construct the maximum likelihood phylogenetic tree reconstruction in RAxML with ascertainment bias correction, the general time-reversal-gamma distribution model of nucleotide substitution and ascertainment bias was used. One thousand bootstrap pseudoreplicates evaluated node robustness.
Statistical Analysis
Characteristics of patients with XDR-TB at treatment initiation were stratified by HIV status and by TB lineage. Frequencies and percentages of TB drugs used were described. Comparisons used the x 2 test or Fisher exact test for categorical variables. Continuous variables were summarized with the median and interquartile range (IQR). Unfavorable treatment outcomes included death, treatment, failure, or loss to follow-up, and favorable treatment outcomes included cure and treatment completion. CD4 count/mm 3 was defined as the first CD4 count recorded for each patient.
Survival analysis for mortality was calculated from time of XDR-TB treatment initiation until time of death or censoring. Duration was calculated in days and then converted into months by dividing by 30.4. Kaplan-Meier curves were stratified by risk factors for mortality. Tests between strata were assessed using the log-rank test.
Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated from Cox-proportional hazard models for mortality and favorable treatment outcomes. Person-time for favorable outcomes analysis was calculated from time of XDR-TB treatment initiation to the favorable outcome, censored events, or end of follow-up at 24 months. Bivariate analysis was used to assess the relationship between exposure variables and time-to-event variables. Multivariable models were adjusted for variables that were of significance according to the literature, and proportional hazards assumptions were tested.
Subdistributional hazard models, with death as a competing risk, and Cox-proportional hazard models were generated to identify patient characteristics associated with net MTB sputum culture conversion. Statistical analysis was performed using SAS version 9.4 software (SAS Institute, Cary, NC) and STATA version 12.0 (StataCorp LP, College Station, TX).
RESULTS
During the study period, 110 patients with XDR-TB aged 18 years or older presented at a public TB specialist hospital in KwaZulu-Natal Province, South Africa. Of these, 5 did not meet study eligibility criteria (1 was incarcerated and ineligible by protocol, 3 were determined to not be XDR-TB, and 1 was lost to initial treatment), and 105 were enrolled and provided data for analysis. Most patients were women (53.3%) and younger than 36 (52.4%) years; 41 (58.1%) patients had a previous history of MDR-TB treatment, and 97 (92.4%) had a previous history of drug-sensitive TB. Median CD4 cell count/mm 3 at XDR-TB treatment initiation was 192 (IQR 117-390), 66/80 (82.5%) patients with HIV infection were receiving ART at the time of XDR-TB treatment initiation [after treatment initiation, an additional 9 patients started ART (93.8%)]. Over the course of the study, median time to sputum culture conversion was 65 days (IQR 34-99) ( Table 1) . Median follow-up time was 18.1 months (IQR: 6.5-24.1).
Treatment Outcomes
Treatment outcomes were determined at 24 months. Thirty-three (31.4%) patients had favorable treatment outcomes (25.7% were cured, and 5.7% completed treatment); 72 patients (68.6%) had unfavorable outcomes: 43 patients died (41%), 17 patients were lost to follow-up (16.2%), and 12 patients failed to complete treatment (11.4%) ( Table 2) . Of the 43 reported deaths, TB was the likely proximate cause for 21 (48.8%) cases (including 3 cases of massive hemoptysis), and TB was excluded as the proximate cause of 5 deaths (including 3 cases of acute renal failure). In 17 cases, the cause of death was unknown, occurring outside of the hospital setting. One patient seroconverted to HIV-infected during 24 months of follow-up. Among those who qualified for cotrimoxazole treatment (HIV-infected and with CD4 count ,250/mm 3 ), 57.1% (24/42) were ever treated with cotrimoxazole. Among the 5 HIV-coinfected patients who never started ART, the median CD4 count at XDR-TB treatment initiation was 415.5 (IQR: 271.5-506.5). The 5 who did not start ART were enrolled in the study over a period of July 2009 to January 2011. All had a previous history of TB. They did not seem to differ from those who started ART by demographic or other factors. Among those who did start ART, the median CD4 count was 187.0 (IQR: 113.5-347.0). We additionally followed patients out to 36 months (12 months after treatment completion) using the criteria suggested by Lange et al to assign outcomes. Using these criteria, 6 additional patients were reclassified as failure because they did not convert within 6 months or reverted to culture positive after 24 months, 1 additional patient died, and 7 patients were considered undeclared because we did not have sufficient post-24-month follow-up. The median number of XDR-TB drugs in the treatment regimen was 9 (IQR: 7-11), and the most commonly used drugs among all patients (n = 105) were pyrazinamide (96.2%), ethambutol (91.4%), moxifloxacin (91.4%), para-aminosalicylic acid (90.5%), and terizidone (90.5%) and capreomycin (88.6%) ( 
Whole Genome Sequencing
Most XDR-TB isolates that were sequenced (n = 50) were of the LAM4/KZN lineage (68%), followed by Beijing (10%), PGG1,LIN-2 (10%), S,PGG2,LIN-4 (10%), and "Other" isolates (12%), which include CAS1-Kili, PGG1, LIN-3; T3,PGG3,LIN-4; and X3,PGG2,LIN-4 ( Table 2 , Supplemental Digital Content http://links.lww.com/QAI/B204). Among those with WGS available, 74% had a previous history of MDR-TB compared with 44% of those who did not have WGS available (P , 0.01). In WGS, mean pairwise SNP difference between LAM4 isolates was 50.37. When we excluded 2 outlier genomes, the mean pairwise SNP difference between the LAM4 isolates was 17.41, and when we used the original Tugela Ferry MTB isolate as a reference, the mean pairwise SNP difference was 10.71 (Fig. 1) .
Statistical Analysis
In survival analysis, XDR-TB/HIV-coinfected patients receiving ART had an improved mortality compared with XDR-TB/HIV patients who never received ART (HR: 0.28, 95% CI: 0.08 to 0.98, P = 0.05) (Fig. 2) . Mean time to event was 17.34 months, and for patients not receiving ART, median time to event was 6.61 (Fig. 2B) . Among those who did not culture convert, median time to event was 13.82 months (Fig. 2C) . In univariate analysis, patients who had MTB sputum culture conversion had a 95% lower hazard for mortality (HR: 0.05, 95% CI: 0.02 to 0.17, P , 0.0001) than patients who did not (Table 3 , Supplemental Digital Content http://links.lww.com/QAI/B204). In an analysis of risk factors associated with favorable treatment outcomes (defined as cure and completed treatment), no variables were significantly associated with the outcome (Table 4 , Supplemental Digital Content http://links.lww.com/QAI/B204).
In a competing risk analysis, with death as the competing risk, there were no predictor variables that were significantly associated with MTB sputum culture conversion (S5). In multivariable analysis of competing risks, patients with XDR-TB/HIV who received ART at XDR-TB treatment initiation were more likely to experience net MTB sputum culture conversion than patients not receiving ART (adjusted subdistribution HR: 1.45, 95% CI: 0.44 to 4.75, P = 0.37); however, this was not statistically significant (Table 5 , Supplemental Digital Content http://links.lww.com/QAI/B204).
DISCUSSION
The findings from our study are important because they provide strong evidence that despite improved ART coverage, and reasonable adherence to ART, XDR-TB/HIV mortality remains unacceptably high, and therefore, improved HIV care and ART treatment alone may not be sufficient to improve XDR-TB/HIV outcomes. In this study, we found a high percentage of patients with XDR-TB/HIV receiving ART at baseline, with high rates of HIV testing before XDR-TB treatment. Despite high ART coverage, mortality rates and treatment outcomes remained poor and loss to follow-up (previously default) during treatment remained high. Failure of XDR-TB to respond to treatment, as measured by culture conversion, was the single greatest risk factor for mortality.
Although there was improved TB culture conversion with ART from XDR-TB treatment initiation in a competing risk analysis, the absolute difference was modest and not statistically significant on multivariable analysis through 24 months after treatment initiation. WGS revealed that MTB of a single lineage and with relatively few SNP differences comprised the majority of cases of XDR-TB in our study. The isolates were taken from patients in different parts of the province over the span of 3 years, and they represent MTB isolates from only the fraction of patients with XDR-TB who successfully present to care. Given that these isolates are linked genetically, but not linked in terms of conventional epidemiology, this reinforces the idea that there is a large, uncontrolled XDR-TB epidemic in KwaZulu-Natal, South Africa.
Low rates of successful treatment outcomes among patients with XDR-TB/HIV have been previously described.
In one study previously reported by this group, only 61% of XDR-TB/HIV-coinfected patients were receiving ART, compared with 82.5% within this cohort, and the rate of mortality was 42%, compared with 41% in this cohort. 9 Dheda et al 11 (2010) reported that 62% of patients with XDR-TB in their study who were living with HIV were on highly active ART, and the mortality was 36% among the entire cohort, and 55% among those living with HIV. A more recent article by Olayanju et al 23 compared outcomes between 2 cohorts of patients with XDR-TB , of which 49.3% were HIV-infected. In the nonbedaquiline cohort, 85.8% of the cohort had an unfavorable outcome and 33.8% died, compared with the bedaquiline cohort, of which 33.8% had an unfavorable outcome, and 14.7% were deceased. Adherence for this cohort has been previously described, and 6-month selfreported adherence was found to be 88.2% for antiretrovirals and 67.7% for TB. 24 The findings from our study are important because they provide strong evidence that despite improved ART coverage, and reasonable adherence to ART, XDR-TB/HIV mortality remains unacceptably high.
Irrespective of HIV status, outcomes of XDR-TB are poor. A systematic review of treatment outcomes conducted by Jacobson et al (2010) found that among patients with XDR-TB who were not HIV-infected, 43.7% experienced favorable treatment outcomes (compared with 31.4% in the PROX study) and approximately 20.8% died, although this figure varied according to the setting, with mortality as high as 98% among patients identified in the Tugela Ferry outbreak. 2, 25 In this study, we found that HIV status was not associated with mortality.
One of the primary limitations to this study was a small sample size, which subsequently may have led to underpowered statistical analysis for the modeling. WGS was available for only 50 patients due to sample viability. In addition, as this study was conducted at a tertiary referral hospital, many patients were not referred or treated and did not start therapy, resulting in an initial selection bias. It is likely that patients who were successfully referred for treatment initiation differed in important ways from those who were not, so in addition to selection bias, there may have been a survivor bias inherent within the selection process. However, during the study period, this was the only center in the province to start XDR-TB treatment and so the study population was representative of those seeking care in that regard. In addition, although this was a prospective study, HIV viral load data were incomplete, and there were limited data on comorbid conditions and opportunistic infections.
The findings from our study are important because they provide strong evidence that despite improved HIV care and substantially higher rates of ART, and cotrimoxazole prophylaxis, mortality remains high and improved HIV care and ART treatment alone may not be sufficient to improve XDR-TB/HIV outcomes. Fortunately, new medications for drugresistant TB are being actively rolled out, and new regimens are being studied. Although our study was conducted before the introduction of these new drugs, the prospective design allows for our study to act as a baseline to which future studies can be compared. As new drugs such as bedaquline and new regimens such as the NiX regimen (bedaquiline, pretomanid, and linezolid given orally for 6 months) become available, it will be important to monitor treatment carefully to ensure that the benefits seen in clinical trials are translated to and reproduced in high-burden, low-resource settings. 26 
